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Abstract 
Feline immunodeficiency virus (FIV) is a lentivirus of domestic cats worldwide. 
Diagnosis usually relies on antibody screening by point-of-care tests (POCT), e.g. by 
enzyme-linked immunosorbent assays (ELISA), and confirmation using Western blot 
(WB). We increasingly observed ELISA-negative, WB-positive samples and aimed to 
substantiate these observations using 1,194 serum/plasma samples collected 1998–
2019 primarily from FIV-suspect cats. While 441 samples tested positive and 375 
tested negative by ELISA and WB, 81 samples had discordant results: 70 were false 
ELISA-negative (WB-positive) and 11 were false ELISA-positive (WB-negative); 297 
ambiguous results were not analyzed further. The diagnostic sensitivity and 
specificity of the ELISA (82% and 91%, respectively) were lower than those reported 
in 1995 (98% and 97%, respectively). The diagnostic efficiency was reduced from 
97% to 86%. False ELISA-negative samples originated mainly (54%) from 
Switzerland (1995: 0%). Sixty-four false ELISA-negative samples were available for 
POCT (SNAPTM/WITNESSR): five were POCT-positive. FIV RT-PCR was positive for 
two of these samples and was weakly positive for two ELISA- and POCT-negative 
samples. Low viral loads prohibited sequencing. Our results suggest that FIV 
diagnosis has become more challenging, probably due to increasing travel by cats 
and the introduction of new FIV isolates not recognized by screening assays. 
5 
 
Zusammenfassung 
Das feline Immunschwächevirus (FIV) ist ein weltweit vorkommendes Lentivirus der 
Katze. Üblicherweise erfolgt die Diagnose mithilfe eines Antikörper-Screeningtests 
(POCT) z.Bsp. eines enzyme-linked immunosorbent assays (ELISA) und der 
Bestätigung durch den Western Blot (WB). Vermehrt wurden ELISA-negative, WB-
positive Proben beobachtet. Die Untersuchung von 1,194 Serum-/Plasmaproben FIV-
verdächtiger Katzen aus dem Zeitraum von 1998-2019 mittels ELISA und WB, ergab 
441 positive, 375 negative und 81 Proben mit unklarem Ergebnis: 70 davon falsch 
ELISA-negativ (WB-positiv) und 11 falsch ELISA-positiv (WB-negativ); nicht 
analysiert wurden 297 Proben ohne eindeutiges WB Ergebnis. Die Sensitivität und 
Spezifität des ELISAs (82%/91%) waren niedriger als 1995 (98%/97%). Die 
diagnostische Effizienz war von 97% auf 86% reduziert. Falsch ELISA-negative 
Proben kamen zu 54% aus der Schweiz (1995: 0%). Vierundsechzig falsch ELISA-
negative Proben standen für POCT (SNAPTM/WITNESSR) zur Verfügung: fünf waren 
positiv. Zwei dieser Proben waren ebenfalls in der RT-PCR-positiv und zwei ELISA- 
und POCT-negative Proben schwach RT-PCR-positiv. Geringe Virusmengen 
verhinderten Sequenzieren. Unsere Ergebnisse legen nah, dass die Diagnose von 
FIV schwieriger geworden ist. Dies hängt möglicherweise mit erhöhter Mobilität von 
Hauskatzen und der Einführung neuer FIV Isolate zusammen, deren Erkennen von 
herkömmlichen Screeningtests nicht mehr gewährleistet ist. 
 
 
 
 
 
 
 
Viruses 2019, 11, 697; doi:10.3390/v11080697 www.mdpi.com/journal/viruses 
 
Article 
Decreased Sensitivity of the Serological Detection of 
Feline Immunodeficiency Virus Infection Potentially 
Due to Imported Genetic Variants 
Julia Frankenfeld 1, Theres Meili 1, Marina L. Meli 1, Barbara Riond 1, A. Katrin Helfer-
Hungerbuehler 1, Eva Bönzli 1, Benita Pineroli 1 and Regina Hofmann-Lehmann 1,* 
1 Clinical Laboratory, Department for Clinical Diagnostics and Services, and Center for Clinical Studies, 
Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland; 
jfrankenfeld@vetclinics.uzh.ch (J.F.); tmeili@vetclinics.uzh.ch (T.M.); mmeli@vetclinics.uzh.ch (M.L.M.); 
briond@vetclinics.uzh.ch (B.R.); khungerbuehler@vetclinics.uzh.ch (K.H.H.); Switzerland 
eboenzli@vetclinics.uzh.ch (E.B.); bpineroli@vetclinics.uzh.ch (B.P.); rhofmann@vetclinics.uzh.ch (R.H.L.) 
* Correspondence: rhofmann@vetclinics.uzh.ch; Tel.: +41-44-635-83-11 
Received: 4 July 2019; Accepted: 29 July 2019; Published: 31 July 2019 
Abstract: Feline immunodeficiency virus (FIV) is a lentivirus of domestic cats worldwide. Diagnosis 
usually relies on antibody screening by point-of-care tests (POCT), e.g. by enzyme-linked 
immunosorbent assays (ELISA), and confirmation using Western blot (WB). We increasingly observed 
ELISA-negative, WB-positive samples and aimed to substantiate these observations using 1194 
serum/plasma samples collected from 1998 to 2019 primarily from FIV-suspect cats. While 441 samples 
tested positive and 375 tested negative by ELISA and WB, 81 samples had discordant results: 70 were 
false ELISA-negative (WB-positive) and 11 were false ELISA-positive (WB-negative); 297 ambiguous 
results were not analyzed further. The diagnostic sensitivity and specificity of the ELISA (82% and 
91%, respectively) were lower than those reported in 1995 (98% and 97%, respectively). The diagnostic 
efficiency was reduced from 97% to 86%. False ELISA-negative samples originated mainly (54%) from 
Switzerland (1995: 0%). Sixty-four false ELISA-negative samples were available for POCT 
(SNAPTM/WITNESSR): five were POCT-positive. FIV RT-PCR was positive for two of these samples 
and was weakly positive for two ELISA- and POCT-negative samples. Low viral loads prohibited 
sequencing. Our results suggest that FIV diagnosis has become more challenging, probably due to 
increasing travel by cats and the introduction of new FIV isolates not recognized by screening assays. 
Keywords: Feline immunodeficiency virus; retrovirus; lentivirus; domestic cat; serology; point-of-care 
test; Western blot; gold standard; veterinary sciences 
 
1. Introduction 
Feline immunodeficiency virus (FIV) is a lentivirus with a worldwide distribution [1-3]. Infection 
with this retrovirus can lead to immunodeficiency in domestic cats [1, 2, 4] while the pathogenic 
potential in wild felids is less well known [3, 5-9]. Due to a lack of proofreading capacity of the reverse 
transcriptase, there is a high error rate during replication and low replicative fidelity [10-13]. Currently, 
five major clades or subtypes of FIV (A-E) have been described based on phylogenetic analyses of the 
variable regions 3–5 of the FIV env gene as well as a portion of the gag gene [14-18]. While there is some 
genetic intra-clade diversity, the genetic distance between different FIV clades was found to be more 
than 17% [14, 15, 17]. Recently, strains were tentatively assigned to new clades in Brazil, Turkey, the 
USA, Portugal and New Zealand, of which the two latter clusters exhibit the new subtypes F and U-
NZenv [19-24].
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FIV clade A strains are found worldwide [16, 25-28]; the other clades show varying geographic 
prevalences, and the separate evolution of these clades in geographical distinct areas [14, 29] and 
introduction into other areas has been proposed [15, 26, 30-33]. The most prevalent FIV clades found in 
Europe are A and B, with clade A being predominant in Northern Europe (Germany, Benelux, and the 
UK) [16, 32, 34-36] and clade B occurring more frequently in Southern Europe (Portugal, Italy, Austria, 
Croatia, and Turkey) [16, 20, 24, 29, 34, 37]. In North America, FIV clades A, B and C have been described 
[15, 16, 31, 33]. In South America, clades A, B, and E have been reported, with clades B and E being 
predominant and clade E only being described in this geographic area so far [18, 28, 38-41]. Limited 
information on the FIV strains and clades is available for Asia. Clade C seems to be the most common 
in Taiwan and Vietnam [30, 42, 43]. Subtype A has been described in China [44], and subtypes A, B, C 
and D have been reported in Japan. B and D were the most prevalent subtypes, and clade D was found 
only in Japan and Vietnam [26, 30]. Clades A and B are distributed in Australia [45, 46], while A, C and 
U-NZenv are found in New Zealand [27]. Interestingly, a cat can be infected concurrently with several 
FIV strains [47-49]. Overall, the geographically restricted evolution of some subtypes, such as D, E and 
F, and the increasing import of domestic cats, some of them possibly coinfected with FIV strains of more 
than one subtype, might result in intersubtype recombinants and changes in the locally prevailing FIV 
clades [16, 17, 26, 27, 30-34, 41, 42, 50]. 
The laboratory diagnosis of FIV infection primarily relies on the detection of antibodies against FIV 
in infected cats, since FIV loads in the peripheral blood are usually very low and antibodies to FIV are 
an almost universal feature in FIV-infected cats [51-57]. Furthermore, genetic diversity is known to lead 
to challenges in the molecular diagnosis of the infection [31, 54, 58-60]. The recombination of viral strains 
and emerging antigenic variants might also result in antibodies that are no longer recognized by 
common diagnostic tests [53, 61-64]. For practitioners, diagnostic point-of-care tests (POCT) that quickly 
detect antibodies are the method of choice [53, 65-69]. Antibodies against the FIV transmembrane 
protein (TM) are the most reliable in terms of both their initial appearance post infection and their 
duration of detection in the blood [52, 53, 70-72]. Therefore, many POCT and enzyme-linked 
immunoassays (ELISA) used in diagnostic laboratories use FIV-TM as the capture antigen, but capsid 
protein has also been added to some tests [56, 66, 68, 73]. The detection of FIV antibodies by Western 
blot (WB) is considered the gold standard and is used for the confirmation of FIV diagnosis in cases of 
ambiguous POCT and ELISA results [56, 65, 70, 74-77]. In addition, WB is recommended to confirm any 
ELISA- and POCT-positive results in countries with a low FIV prevalence, since the positive predictive 
value of positive ELISA and POCT results is low under these circumstances [56, 76, 78]. 
For many years, samples from cats suspected of FIV infection (ambiguous or positive POCT results) 
have been sent to our laboratory for the confirmation of FIV diagnosis using Western blotting [70, 74]. 
Furthermore, we have been receiving samples for primary FIV screening purposes with FIV-TM ELISA 
[53]. During routine testing, samples would be sporadically found that were negative for FIV-TM ELISA 
and positive for WB. This phenomenon had already been described during the development of the FIV-
TM ELISA in 1995, but this was found for only four of 194 tested samples, and they were all from cats 
that lived outside of Switzerland [53]. 
We hypothesized that the number of FIV infections that are undetectable by FIV-TM ELISA and 
POCT has increased over the years due to an increased number of cats with a travel or import history, 
which has thus introduced novel FIV isolates into the sample population. Thus, the aim of this study 
was to systematically test samples that have been sent to our laboratory over two decades (1998–2019) 
using FIV-TM ELISA as well as WB, which is the gold standard for FIV testing. In cases of discrepant 
results with sufficient sample volumes, two commercially available POCT (SNAPTM Combo Plus FeLV 
Ag/FIV Ab, IDEXX Laboratories, Westbrook, ME, USA; WITNESSR FIV, Zoetis, Delémont, Switzerland) 
and RT-PCR assays [58, 60, 79, 80] (FTvet Feline Anaemia I, Fast Track Diagnostics, Esch-sur-Alzette, 
Luxembourg) were performed. In addition, an attempt was made to sequence all RT-PCR-positive 
samples. The study included a total of 1194 samples, including 536 samples from FIV-infected cats, 
based on WB analysis.
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2. Materials and Methods 
2.1. Serum samples 
Feline plasma and serum samples submitted to the Clinical Laboratory, Vetsuisse Faculty, 
University of Zurich, Switzerland, from the end of 1998 until the beginning of 2019, were available for 
this study. The samples had been taken by veterinary practitioners as part of a diagnostic workup and 
were sent to the laboratory for routine diagnostic purposes; only leftover samples were used, and no 
additional blood volume was collected for the current study. No ethical approval was necessary for this 
study in compliance with Swiss regulations [81]. 
2.2. FIV-TM ELISA 
The FIV-TM ELISA was performed as previously described [53], with some modifications. Feline 
serum samples were diluted 1:4,500 and tested in duplicate. A positive and negative control was run 
with each plate. For the positive control, pooled sera from experimentally FIV-infected cats were used 
for every run [82]. The negative control consisted of heat-inactivated bovine serum. The plate was then 
incubated for one hour at 37°C and washed three times. Horseradish peroxidase-labeled goat anti-cat 
immunoglobulin G (H+L) (Jackson Immunoresearch Laboratories, West Grove, PA, USA) was used as 
a conjugate and was diluted 1:1,000. The absorbance was measured by an ELISA plate reader 
(SPECTRAmax PLUS 384, Bucher Biotec AG, Basel, Switzerland) at 405/550 nm. The optical density 
(OD) values of the cat serum samples were expressed as percentages of the value obtained from the 
positive control sera. Results that were >50% in comparison with the positive control were classified as 
positive, whereas those that were <10% were classified as negative and those that were 10-50% were 
classified as ambiguous. 
2.3. FIV WB 
The WB was conducted as previously described using 500 ng of gradient-purified FIV Z2, which 
was propagated in feline specified-pathogen free lymphocyte cultures in the presence of recombinant 
interleukin-2 [53, 70, 74]. Feline serum samples were diluted 1:50 and incubated with WB strips 
overnight on a rocker platform at room temperature. A peroxidase-labeled goat anti-cat 
immunoglobulin G (H+L) conjugate (Jackson Immunoresearch Laboratories) was diluted 1:1,000 and 
incubated for two hours; after a washing step, the substrate (4-chloronaphtol, HRP Color Development 
4CN, Bio-Rad Laboratories, Hercules, CA, USA) was added. A positive (serum from a FIV-positive cat) 
and negative control (buffer only) were run for each blot. The WB was considered positive if two bands 
with a molecular weight of 15,000 (p15) and 24,000 (p24) Dalton, respectively, were recognizable on the 
blotting strip [74]. If both bands were absent, the sample was judged as WB-negative. Samples that 
yielded only one band, either p24 or p15, were judged as inconclusive. WB-positive and negative results, 
but not inconclusive results, were included in the statistical analysis. 
2.4. FIV point-of-care testing 
Depending on the remaining sample volume, ELISA-negative and WB-positive samples were 
tested using two different point-of-care tests: WITNESSR FIV (Zoetis, Delémont, Switzerland) and/or 
SNAPTM FeLV Ag/FIV Ab Combo Plus (IDEXX Laboratories, Westbrook, ME, USA). The kit materials 
and samples were allowed to warm to room temperature before performing the test (SNAPTM) or were 
used directly (WITNESSR) according to the manufacturer’s recommendations, and the reading of the 
results was performed 10 minutes after the activation of the test. 
2.5. FIV RT-PCR analysis 
ELISA-false negative (WB-positive) samples that underwent one or both POCT tests and that had 
enough remaining volume for additional tests (n = 59) were further analyzed by RT-PCR. Additionally, 
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a few ELISA false-negative samples with too little volume for combined POCT and RT-PCR analyses (n 
= 6) underwent only RT-PCR to increase the chance of viral RNA confirmation in at least one discordant 
sample. Moreover, some samples from FIV-infected cats (ELISA- and WB-positive) were included as 
controls. Total nucleic acid was extracted from 100 µl of EDTA anticoagulated blood (1/65) using the 
MagNAR Pure LCR Total Nucleic Acid Isolation Kit (Roche Diagnostics GmbH, Mannheim, Germany) 
or RNA from 140 µl anticoagulated plasma or serum (64/65) with the QIAampR Viral RNA Kit (QIAGEN 
GmbH, Hilden, Germany). Notably, prior to nucleic acid extraction, the samples had undergone an 
unknown number of freeze-thaw cycles, and some of them had been stored for up to 20 years at -20°C. 
Negative controls consisting of 100 or 140 µl of phosphate buffered saline were prepared with each 
extraction batch to monitor cross-contamination. 
Nucleic acid samples were analyzed by real-time RT-PCR that allowed the amplification of various 
FIV isolates from clades A and B as described previously [58, 60], with the following modifications: the 
final reaction volume of 25 µl contained 800 nM of each primer (FIV551f/FIV571r), 160 nM of the 
fluorogenic probe (FIV581p), 12.5 µl 2x RT qPCR Mastermix and 0.125 µl of a master mix containing 
6.25 U Euroscript reverse transcriptase and 2.5 U RNase inhibitor (One Step RT qPCR MasterMix Plus 
Low ROX, Eurogentec Headquarters, Seraing, Belgium). The cycling conditions were as follows: 30 
minutes at 48°C for reverse transcription, followed by an initial denaturation for 10 minutes at 95°C and 
45 amplification cycles at 95°C for 15 seconds and 60°C for 1 minute as previously described by using a 
7500 Fast Real-Time PCR System (ThermoFisher Scientific, Zug, CH) [60]. A second real-time RT-PCR 
was performed according to a modified version of the method used by Wang et al. [80], which used 900 
nM of both the upstream (FIV_gag_upstr: 5’- ATG GGG AAY GGA CAG GGG CGA GA-3’) and 
downstream (FIV_gag_downstr: 5’- TCT GGT ATR TCA CCA GGT TCT CGT CCT GTA-3’) primers 
and 250 nM fluorogenic probe (FIV_gag_F2ABCEmIM 5’-FAM-TGG CCA TWA ARA (iQ500)GAT GYA 
GTA ATG TTG CTG TAG G-BHQ1-3’), 0.625 µl (40 U/µl) RNasinR Plus (Promega, Madison, WI, USA), 
12.5 µl 2x RT qPCR Reaction Mix, 0.5 µl SuperscriptTM III RT/PlatinumR Taq mixture and 0.05 µl ROX 
(all from the SuperscriptTM III PlatinumTM One-Step qRT-PCR kit, ThermoFisher Scientific, Carlsbad, 
CA, USA) in a final volume of 25 µl. The reaction mix underwent reverse transcription at 50°C for 15 
minutes, denaturation and activation for 2 minutes at 95°C and 45 cycles of 95°C for 15 seconds and 
60°C for 30 seconds. In addition, the nucleic acid samples were tested using a commercially available 
real-time RT-PCR kit (FTvet Feline Anaemia I, Fast Track Diagnostics, Esch-sur-Alzette, Luxembourg). 
Finally, a semi-nested RT-PCR was performed that amplified a 470 bp-long sequence from the FIV clade 
A and B gag gene using primers previously described [79, 83] with a concentration of 200 nM of each 
primer in the first round and 1 µM of each primer in the second round. The final reaction volume was 
25 µl in both rounds; 12.5 µl 2x Reaction Mix, 1 µl SuperscriptR polymerase (SuperscriptR III One-Step 
RT-PCR with PlatinumR Taq Kit, ThermoFisher Scientific) and 0.31 µl (40 U/µl) RNasinR Plus (Promega) 
were used in the first round, whereas 2.5 µl 10x buffer, 1.5 µl MgCl2, 1.25 µl (5U/µl) Taq DNA 
Polymerase (Sigma-Aldrich, St. Louis, MO, USA) and 0.5 µl dNTPs (ThermoFisher Scientific, Vilnius, 
Lithuania) were used in the second round. Briefly, a reverse transcription step was performed for 30 
minutes at 55°C, followed by the first round of PCR, which consisted of 2 minutes at 94°C, 40 cycles of 
15 seconds at 94°C, 1 minute at 53°C and 1 minute at 73°C, and a final step of 5 minutes at 68°C. Then, 
for the second round, 5 µl of the first round PCR product was used with the following cycling 
conditions: five minutes at 95°C, followed by 40 cycles of 30 seconds at 95°C, 30 seconds at 58°C and 1 
minute at 72°C and a final elongation step of 10 minutes at 72°C. The PCR products from the second 
round of PCR were analyzed by agarose gel electrophoresis (2%). All bands of the expected length were 
purified (QIAQuickR Gel Extraction Kit, QIAGEN GmbH) and submitted for sequencing (Microsynth 
AG, Balgach, Switzerland). The sequences were edited and assembled using GeneiousR 11.1.5 software 
(Biomatters, Ltd., Auckland, New Zealand). Using a basic local alignment search tool (NCBI: 
https://blast.ncbi.nlm.nih.gov/Blast.cgi), we aimed to find similarities between the isolated sequences 
and published FIV sequences.
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2.6. Diagnostic sensitivity and specificity of FIV-TM ELISA 
WB has been considered the gold standard to accurately identify FIV positive and negative 
samples. The diagnostic sensitivity, specificity and efficiency of FIV-TM ELISA were calculated. 
2.7. Statistics 
The data were compiled in Microsoft Excel 2016 and analyzed using GraphPad Prism 8 (Version 
8.1.0; GraphPad Prism Software, La Jolla, CA, USA). The frequencies were compared using Fisher’s 
exact test (pF). The ages of the cats in different groups was compared using the Mann-Whitney U-test 
(pMWU). P-values < 0.05 were considered statistically significant. 
3. Results 
3.1. Sample characteristics and results of FIV WB testing 
Of the 1194 cats included in the study, ages were known for 700 cats (59%), and the median age 
was 5.0 years (Table 1). The sex of 712 (60%) cats was known: 192/1194 (16%) and 289/1194 (24%) were 
intact males or castrated males, respectively; 104/1194 (9%) and 127/1194 (11%) were intact or spayed 
females, respectively (Table 1). The samples were obtained from Switzerland (641/1194; 54%), Germany 
(475/1194; 40%), France (53/1194; 4%), Austria (5/1194; 0.4%), Finland (9/1194; 0.8%) and Italy (2/1194; 
0.2%). For nine samples, the country of origin was unknown. 
 
Table 1. Sample characteristics: Sex, age and origin of the cats that underwent FIV WB and ELISA 
testing. 
 All Samples 
WB-Negative/ 
Inconclusive 
Samples1 
WB-Positive 
Samples1 
WB-Positive1, 
ELISA-Positive 
Samples 
WB-Positive1 
Samples With 
Ambiguous 
ELISA Results 
WB-Positive1, 
ELISA-Negative 
Samples 
Total 1194 411/247 536 441 25 70 
Sex       
- m 192 65/36 91 74 2 15 
- mc 289 64/53 172 155 3 14 
- f 104 44/26 34 24 0 10 
- fs 127 67/22 38 31 1 6 
- unk 482 171/110 201 157 19 25 
Age (y)       
- <6 months2 46 23/12 11 6 1 4 
- 6 months to <2 y 113 49/25 39 29 0 10 
- 2 to <6 y 210 70/48 92 74 4 14 
- 6 to <10 y 151 44/31 76 63 0 13 
- 10 to <14 y 125 45/25 55 50 0 5 
- 14 to <18 y 47 18/14 15 8 0 7 
-18 to <23 y 8 6/1 1 1 0 0 
- unk 494 156/91 247 210 20 17 
Origin       
- CH 641 235/145 261 216 7 38 
- DE 475 134/88 253 215 11 27 
- FR 53 30/9 14 2 7 5 
- AT 5 3/2 0 0 0 0 
- FI 9 5/3 1 1 0 0 
- IT 2 1/0 1 1 0 0 
- unk 9 3/0 6 6 0 0 
Collection (y)       
1998–2003 252 99/28 125 117 3 5 
2004–2008 211 44/53 114 83 7 24 
2009–2013 276 124/56 96 84 8 4 
2014–2019 455 144/110 201 157 7 37 
1 FIV-negative and FIV-positive were defined according to the gold standard test, WB; samples producing one band in WB are 
“inconclusive”; 2 maternal antibodies are possible in WB-positive cats known to be younger than 6 months of age; unk = 
unknown; m = male, mc = castrated male, f = female, fs = spayed female; y = years; CH = Switzerland, DE = Germany, FR = 
France, AT = Austria, FI = Finland, IT = Italy.
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3.2. Comparison of WB-Negative and WB-Positive cats 
The results from the FIV WB analyses were used as the gold standard for the determination of FIV 
status in cats [53, 70, 74]. Of the 1194 tested samples, 536 were FIV WB-positive and 411 were FIV WB-
negative, and 247 had inconclusive results because they produced only one band in WB (Table 2). 
 
Table 2. Comparison of FIV WB and FIV ELISA results. 
 WB-Positive WB-Negative WB-Inconclusive2 Total 
ELISA-Positive  
(OD <50% of pc1) 
441 11 36 488 
ELISA-Pegative 
(<10% of pc) 
70 375 205 650 
Ambiguous Result 
(10-50% of pc) 
25 25 6 56 
Total 536 411 247 1194 
1 pc = positive control run with every ELISA; 2 WB-inconclusive samples result in only one band, p24 or p15. 
Of the 536 WB-positive cats, the age of 289 was known; the median age of the WB-positive cats was 
6.0 years (Table 1). Seventeen cats were 0.5 years old or younger; the FIV-positive results in these cats 
could be the result of maternal antibodies. The sex of 335 WB-positive cats was known: the positive 
samples originated from 91 (27%) intact males, 172 (51%) neutered males, 34 (10%) intact females and 
38 (11%) spayed females (Table 1). Most of the WB-positive samples came from Switzerland (n = 261) 
and Germany (n = 253); only a few samples were sent from other countries (Table 1). 
Of the 411 WB-negative cats, the age was known for 255 cats: the median age of the WB-negative 
cats was 4.0 years (Table 1). Information about the sex was available for 240 cats: there were 65 intact 
male (27%), 64 neutered male (27%), 44 intact female (18%) and 67 spayed female cats (28%). WB-
negative samples were sent from Switzerland (n = 235), Germany (n = 134), France (n = 30), Austria (n = 
3), Finland (n = 5) and Italy (n = 1); for three samples, the origin was unknown. 
The samples included in this study were not collected randomly but originated mainly from cats 
who were clinically suspected of FIV infection; nonetheless, some basic descriptive analyses were 
performed. FIV WB-positive cats were significantly more likely to be male, either intact or castrated 
(263/335; 79%) than FIV WB-negative cats (129/240; 54%; pF < 0.0001) (Table 1). The median age differed 
significantly between WB-positive (median age 6.0 years) and WB-negative cats (median age 4.0 years) 
(pMWU = 0.0360). FIV WB-positive samples originated less frequently from Switzerland (261/530; 49%) 
than WB-negative samples (235/408; 58%; pF = 0.0122). 
3.3. Confirmation of FIV-TM ELISA results using FIV WB 
Most of the WB-negative samples (375/411; 91%) were FIV-TM ELISA-negative or showed an 
ambiguous result according to ELISA (25/411; 6%; Table 2). It is recommended that ambiguous FIV-TM 
ELISA results be directly retested by WB. Therefore, they do not pose an imminent problem in terms of 
the diagnosis of FIV infection (false positive/false negative) and were not further analyzed in this study. 
However, 3% of the WB-negative samples (11/411) were found to be false-positive according to FIV-TM 
ELISA. Of the 536 samples that were FIV WB-positive, 441 (82%) were also TM ELISA-positive, and 25 
(5%) revealed an ambiguous result. Remarkably, 70 WB-positive samples (13%) were negative 
according to TM ELISA (Table 2). 
The diagnostic sensitivity (true positives/all positives) of FIV-TM ELISA was 82% (441/536); the 
diagnostic specificity (true negatives/all negatives) was 91% (375/411), and the diagnostic efficiency 
(correct tests/all tests) was 86% (816/947).
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3.4. False ELISA-Positive samples (WB-Negative and FIV-TM ELISA-Positive) 
Overall, 11 cats were false-positive according FIV-TM ELISA (WB-negative but ELISA-positive; 
Table 3). For eight samples, a sufficient volume was available to test them also using one or both of the 
POCT. Two samples tested negative in both POCT, and six were positive in at least one or both of the 
POCT performed (Table 3). For three samples, no POCT could be performed. POCT-negative samples 
had OD values in the FIV-TM ELISA in the low positive range, according to our definition (positive 
>50% of the positive control). POCT-positive samples had, with one exception, OD values >100% of the 
positive control in the FIV-TM ELISA. 
 
Table 3. Characteristics of the 11 false ELISA-Positive samples (FIV WB-Negative and FIV-TM ELISA-
Positive). 
Sample 
ID 
Age of Cat 
(Years) 
Sex of 
Cat 
Year of 
Sample 
Collection 
Origin of 
Sample 
(Country) 
ELISA (% 
of pc) 
SNAPTM 
POCT 
WITNESSR 
POCT 
1322 15 m 1999 CH 64.0 neg neg 
1383 unk m 2000 CH 60.0 nt nt 
1436 unk unk 2000 CH 133.7 nt pos 
1607 9 m 2004 DE 149.4 pos pos 
1758 14 fs 2007 DE 70.7 pos pos 
1892 3 mc 2009 CH 75.0 neg neg 
1995 6 f 2011 CH 107.9 pos pos 
2021 12 fs 2011 CH 51.0 nt nt 
2022 10 unk 2011 CH 51.0 nt nt 
2023 0.4 m 2011 CH 108.8 pos pos 
41673826 7 fs 2017 CH 102.5 nt pos 
unk = unknown; m = male, f = female, mc = castrated male, fs = spayed female; nt = not tested since no more material was 
available; neg = negative, pos = positive; pc = positive control; CH = Switzerland, DE = Germany. 
3.5. False ELISA-Negative results (WB-Positive and FIV-TM ELISA-Negative) 
The characteristics of the cats with false-negative ELISA results (WB-positive but ELISA-negative) 
are summarized in Table 1, and the data for each cat are given in Table 4. Such samples originated more 
frequently from male cats (29/70; 41%) than from female cats (16/70; 23%). The samples were sent mainly 
from Switzerland (38/70; 54%) or Germany (27/70; 39%); five samples were from France (Table 1). The 
median age of cats with false-negative ELISA results (5.0 years; Table 1) was lower than that of cats with 
FIV WB- and ELISA-positive results (6.0 years; Table 1), and a minimum age of two months was 
observed in both groups. The oldest cat with a false-negative ELISA result was 16 years old, while 
among the WB- and ELISA-positive cats, 18 years was the maximum age. For several sampling years, 
there were only one or two false-negative cases per year (<10% of all WB-positive samples sent in the 
respective year), while there were four discordant cases each in 2004 and 2006 and fourteen in 2005 
(17%/41%/31% of all WB-positive samples in 2004/2005/2006, respectively). The discordant samples 
represented 15% of all WB-positive samples in 2014 (n = 3), 29% in 2015 (n = 12), 24% in 2016 (n = 11) 
and 19% in 2017 (n = 8) (Tables 1 and 4).
 
Table 4. Characteristics of the 70 false ELISA-Negative samples (FIV WB-Positive and FIV-TM ELISA-
Negative). 
Sample 
ID 
Age of Cat 
(Years) 
Sex of 
Cat 
Year of 
Sample 
Collection 
Origin of 
Sample 
(Country) 
SNAPTM 
POCT 
WITNESSR 
POCT 
ELISA 
(% of pc) 
RT-PCR 
1343 unk unk 1999 CH neg neg 1.5 neg 
1359 1 m 1999 CH neg neg 1.7 neg 
1537 4 mc 2002 DE neg neg 0.0 neg 
1554 8 fs 2003 CH neg neg 3.1 neg 
1574 7 mc 2003 CH neg neg 1.3 neg 
1599 5 f 2004 DE neg neg 0.0 neg 
1621 unk unk 2004 CH nt neg 0.0 neg 
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Sample 
ID 
Age of Cat 
(Years) 
Sex of 
Cat 
Year of 
Sample 
Collection 
Origin of 
Sample 
(Country) 
SNAPTM 
POCT 
WITNESSR 
POCT 
ELISA 
(% of pc) 
RT-PCR 
1633 3 fs 2004 DE neg neg 3.3 neg 
1634 8 f 2004 DE nt nt 1.5 neg 
1648 unk unk 2005 CH nt neg 0.0 neg 
1656 1 m 2005 DE nt nt 0.0 neg 
1666 unk unk 2005 CH neg neg 0.0 neg 
1674 0.21 m 2005 CH neg neg 0.0 neg 
1678 2 mc 2005 DE nt nt 0.0 neg 
1679 0.251 m 2005 DE nt neg 0.0 nt 
1683 0.5 m 2005 DE neg neg 3.0 neg 
1686 unk m 2005 DE neg neg 0.0 neg 
1690 3 unk 2005 CH neg neg 0.6 neg 
1691 13 mc 2005 DE nt nt 0.0 neg 
1692 unk unk 2005 CH nt nt 0.0 neg 
1698 8 m 2005 DE nt neg 0.0 neg 
1699 8 mc 2005 DE neg nt 0.0 nt 
1700 5 mc 2005 DE neg neg 0.0 neg 
1701 14 fs 2006 DE neg nt 0.0 nt 
1703 13 mc 2006 DE nt nt 0.0 neg 
1704 2 mc 2006 CH neg neg 0.0 neg 
1710 3 mc 2006 DE neg nt 0.0 neg 
1781 6 f 2007 DE neg neg 0.0 pos2 
1812 2 f 2008 DE neg neg 2.5 neg 
1886 unk unk 2009 FR pos pos 9.0 pos2 
1922 unk unk 2010 DE nt neg 0.0 neg 
1925 unk unk 2010 FR nt neg 0.0 neg 
0000510
0 
0.251 m 2013 CH pos pos4 6.0 nt 
000 603
8 
unk unk 2014 DE neg neg 0.0 neg 
0000770
2 
unk unk 2014 DE neg neg 0.0 neg 
0000779
2 
0.5 m 2014 DE nt neg 1.6 neg 
0000856
9 
9 mc 2015 DE neg neg 0.0 neg 
0000994
4 
6 mc 2015 CH neg neg 0.0 neg 
0000995
5 
unk unk 2015 FR pos nt 8.0 nt 
0001001
2 
1 m 2015 CH neg neg 0.0 neg 
0001048
9 
0.6 mc 2015 CH nt neg 0.9 neg 
0001054
5 
0.31 f 2015 CH neg neg 2.0 neg 
4138574
9 
10 unk 2015 CH neg neg 0.0 pos3 
4138641
1 
12 unk 2015 CH neg neg 0.2 neg 
4138719
4 
2 unk 2015 CH neg neg 0.4 neg 
4138740
9 
10 unk 2015 CH neg neg 0.2 neg 
4138805
0 
16 unk 2015 CH neg neg 0.3 neg 
4138839
9 
6 unk 2015 CH neg neg 0.1 neg 
413 240
9 
16 unk 2016 CH neg neg 1.5 neg 
0001077
0 
unk f 2016 DE neg neg 0.0 neg 
4139762
7 
8 unk 2016 CH neg neg 0.1 neg 
4139810
2 
6 unk 2016 CH neg neg 0.2 neg 
4140491
8 
14 m 2016 CH neg neg 2.0 neg 
4140667
0 
1 m 2016 CH neg neg 0.0 neg 
414 684
4 
0.5 f 2016 CH neg neg 0.2 neg 
0001145
6 
3 fs 2016 CH neg neg 1.1 neg 
415 142
6 
16 f 2016 CH neg neg 0.3 neg 
4157719
8 
14 m 2016 CH neg neg 0.3 neg 
0001261
2 
4 fs 2016 CH neg neg 9.9 neg 
0001327
4 
unk unk 2017 FR nt neg 0.0 neg 
0001327
6 
unk unk 2017 FR nt neg 4.1 neg 
0001338
1 
7 mc 2017 CH neg neg 1.0 neg 
000 405
9 
0.8 f 2017 DE neg neg 3.0 neg 
0001422
7 
unk unk 2017 DE neg neg 1.6 neg 
0001459
8 
2 m 2017 CH nt neg 0.0 neg 
4166342
6 
16 mc 2017 CH neg neg 0.0 neg 
416 971
4 
7 m 2017 CH pos neg 3.6 pos2 
0001629
5 
unk unk 2018 DE pos neg 5.3 neg 
0001898
0 
0.7 fs 2019 CH neg neg 5.0 neg 
5102817
4 
2 f 2019 CH nt neg 8.0 neg 
1 maternal antibody presence possible; 2 FTvet Feline Anaemia I-positive, CT-value = 38–40; 3 seminested RT-PCR: weakly positive [79, 83]; 4 only 
positive after the regular reading time at 10 minutes; unk = unknown, m = male, f  = female, mc = castrated male, fs = spayed female; nt = not tested 
since no more material was available; neg =  negative, pos = positive; pc = positive control; CH = Switzerland, DE = Germany, FR = France.
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3.6. Further FIV testing of false ELISA-Negative samples 
Of the 70 samples with false-negative ELISA results (WB-positive and TM ELISA-negative), overall 
64 could be tested with at least one of the two POCT, WITNESSR or SNAPTM. Sixty samples had enough 
sample volume to perform the first POCT (WITNESSR), and 48 of these also had enough volume to 
perform the second POCT (SNAPTM). Four additional samples were only tested in the SNAPTM test (in 
total, 52 samples were SNAPTM-tested). In the WITNESSR test, one sample (2%) tested clearly positive 
(Table 4). One sample (sample ID 00005100) showed a band only after the regular reading time at 10 
minutes had passed, and 58/60 (97%) were clearly negative. Of the 52 samples used in the SNAPTM test, 
five samples (10%) were positive and 47/52 (90%) were negative (Table 4). Both samples that tested 
positive or late positive in the WITNESSR test were also positive in the SNAPTM test. The SNAPTM test 
detected two additional samples that were negative in the WITNESSR test and one that was not tested 
with the WITNESSR test. While most of the false ELISA-negative samples had very low ODs according 
to FIV-TM ELISA (0-3%), one of the samples that was double positive in the two POCT and one sample 
that was only tested with the SNAPTM test had ODs of 9.0% and 8.0%, respectively, which were just 
barely below the cut-off value for ambiguous samples (Table 4). An additional sample that was negative 
both POCT showed a result of 9.9% (sample ID 00012612), which was just at the cut-off value of 10% for 
FIV-TM ELISA. The two SNAPTM/WITNESSR double positive samples and the positive sample that was 
tested only with the SNAPTM test were sent from France and Switzerland, and the two samples that 
were detected solely by the SNAPTM test were from Germany and Switzerland. 
Enough sample volume remained for 65 of the 70 discordant samples for nucleic acid extraction 
and to perform FIV RT-PCR. In 6 of the 65 samples tested using RT-PCR, no POCT was performed 
because the remaining material was sufficient only for POCT or RT-PCR. To increase the chance of RT-
PCR confirmation and subsequent sequencing in the discordant samples, it was decided to use RT-PCRs 
for these low volume samples. None of the 65 samples tested positive by a previously described FIV 
real-time RT-PCR that allowed the amplification of various FIV isolates from clades A and B [60] or by 
a modification of a RT-PCR method described by Wang [80]. Three samples tested weakly positive (CT-
values: 38/39/40) according to a commercial real-time RT-PCR kit (FTvet Feline Anaemia I; Table 4). The 
seminested RT-PCR revealed a very weak band for one cat that could not be sequenced. Five ELISA- 
and WB-positive samples were also analyzed as controls using RT-PCR. The five samples had high OD 
values in the TM ELISA (>100%) and were positive in both POCT. All five samples were positive 
according to at least two different RT-PCR assays (Table 5). A BLAST search of the sequences 
demonstrated high similarities to deposited sequences from subtypes A and B. 
 
Table 5. Characteristics of five ELISA- and WB-Positive control samples. 
Sample ID 
Age of Cat 
(Years) 
Sex of 
Cat 
Year of 
Sample 
Collection 
Origin of 
Sample 
(Country) 
ELISA 
(% of pc) 
SNAPTM 
POCT 
WITNESSR 
POCT 
RT-PCR 
1600 2 mc 2004 DE 111.0 pos pos pos1,2 
1622 2 mc 2004 DE 132.8 pos pos pos1,2 
1637 2 mc 2004 CH 182.3 pos pos pos1,2 
00015713 8 mc 2017 CH 179.2 pos pos pos1,2 
00016945 12 fs 2018 CH 265.5 pos pos pos1,2,3 
1 FTvet Feline Anaemia I-positive, CT-value = 30–40; 2 seminested RT-PCR-positive [79, 83]; 3 RT-PCR-positive [60], CT-value = 
33; mc = castrated male, fs = spayed female; pos = positive; pc = positive control; CH = Switzerland, DE = Germany. 
3.7. Inconclusive WB results 
We found 247 samples with inconclusive WB results (Table 2). Of these samples, the majority 
showed antibodies against p24 (230/247, 93%); only a few had a p15 band (17/247; 7%). Of the 247 
samples, 36 were ELISA-positive, of which 30 had OD values ranging from 100% to 440% of that of the 
positive control; 205 tested ELISA-negative and six had an ambiguous result in the FIV-TM ELISA 
(Table 2). Animals with inconclusive WB results are recommended to be retested two to three months 
later. 
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4. Discussion 
In the present study, we investigated our hypothesis that the number of FIV infections in domestic 
cats that are undetectable by FIV-TM ELISA and FIV POCT screening assays has increased over the 
years. We have sporadically identified feline plasma and serum samples that were positive according 
to a confirmatory FIV WB test but negative according to a FIV-TM ELISA screening assay. This 
phenomenon had already been described during the development of the FIV-TM ELISA in 1995, but it 
only concerned four of 194 tested samples, and they all originated from cats that had lived outside of 
Switzerland [53]. We assumed that the number of discordant samples could potentially have risen due 
to an increased number of cats with a travel or import history, which might have resulted in the 
introduction of novel FIV isolates in the sample population. For some of the routine diagnostic cases 
with discordant results, it was confirmed by veterinarians or the owners that the cats had been 
imported. To further investigate our hypothesis, we systematically retested the available feline plasma 
and serum samples submitted to our laboratory over the last two decades (1998–2019) for FIV diagnosis 
or confirmation using FIV-TM ELISA and WB, which was considered the gold standard confirmation 
method. 
The results of our study demonstrate an increased percentage of cats in Central Europe that tested 
FIV-positive by WB, but FIV infection in these cats was unrecognized by FIV-TM ELISA as well as some 
FIV POCT. In the earlier study mentioned above [53], the FIV-TM ELISA used herein had both a high 
diagnostic sensitivity and specificity of 98% and 97%, respectively, when using WB as the gold standard 
[53]. Only 2% of the 194 FIV WB-positive samples were negative according to the TM ELISA [53] 
compared to 70 out of 536 FIV WB-positive samples (13%) collected from August 1998 to February 2019 
and analyzed in the current study. These results were found to indicate a reduced diagnostic sensitivity 
of FIV-TM ELISA of 82%, compared to 98% in 1995. In an attempt to corroborate our results regarding 
the reduced diagnostic sensitivity of FIV-TM ELISA, we also used two POCT for samples with ample 
remaining sample volumes. Remarkably, the two POCT did not recognize many of the discordant 
samples. This observation has serious diagnostic implications, since FIV-TM ELISA as well as FIV POCT 
are used as screening assays for FIV infection; they should have the highest sensitivity possible in order 
not to miss any FIV-infected cats during the primary diagnostic screening step [75]. 
In the earlier study in 1995, the four samples with discordant results originated from cats in 
countries other than Switzerland, and it was hypothesized that FIV-TM ELISA might be specific for 
certain variants of FIV [53, 62, 64]. It was assumed that for the routine testing of cats within Switzerland 
and in the absence of a travel or import history of the cat, the sensitivity of FIV-TM ELISA was sufficient. 
However, in the current study, more than half of the cats with discordant results (54%) had either 
presented to Swiss veterinarians or were represented by samples that had been sent to a Swiss 
laboratory before they were sent for confirmation to our laboratory. This does not necessarily imply that 
all these cats had lived in Switzerland; especially in regions close to the border, the country of the 
veterinarian was not necessarily the country of the origin of the cat. Therefore, a few of these cats with 
an FIV infection that was unrecognized by FIV-TM ELISA might also have lived abroad. In addition, 
the remaining 46% of cats with discordant results originated mainly from Germany, and some 
originated from France. Moreover, based on personal communication with a cat owner, we knew that 
at least one of the cats in Switzerland with a discordant FIV test result was originally imported from 
Greece. Based on earlier studies, FIV subtype A is the predominant subtype in Switzerland and 
Germany, while in southern Europe and Turkey, FIV subtype B is more common [16, 20, 24, 29, 32, 34- 
37]. We were unable to further analyze the prevailing FIV subtypes in the cats with discordant results, 
since only a few were found to be positive using various RT-PCR assays. Only serum or plasma was 
available, so no provirus PCR, which requires anticoagulated whole blood, could be conducted; this test 
usually has a higher sensitivity for FIV infection [84]. Moreover, in the few RT-PCR positive samples, 
the viral RNA loads were too low to sequence the virus. Nonetheless, our data indicate that there is 
currently an increased number of FIV-infected cats in Switzerland as well as in Germany that harbor 
FIV isolates that induce antibodies that are unrecognized by the TM antigen used in FIV-TM ELISA and 
the two FIV POCT. Considering the increased travel of cats in Central Europe, particularly from the 
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East and the South to the North and West of Europe, this might concern more European countries than 
just Switzerland and Germany. 
TM is the immunodominant epitope in FIV that induces the earliest and strongest antibody 
response in cats experimentally infected with FIV [53, 62, 63, 71, 72]. Although the evolutionary rate of 
FIV is rather slow when compared to other lentiviruses [85] and seems to be dependent on the virus 
strain and the infection stage [86], it has been shown that the preferred genetic location for 
recombination is in the envelope (env) gene, which also encodes TM [10, 25, 61, 87]. Additionally, low 
fidelity in the transcription process and a change in the clade distribution could have contributed to the 
increased variability of this protein. The appearance of new viral quasispecies in infected cats has been 
reported as being common [50, 88]. During virus transmission, these quasispecies infect the new host 
and undergo further mutation, hence broadening the genetic diversity [89]. The importance of the 
export of domestic cats with virus strains distinct from those locally predominant might result in a 
change in virus strain distribution or even the spread of regionally clustered subtypes to new areas [16, 
17, 26, 30, 32-34, 42]. Taking into account exchanges between zoos, interhost transmission over wide 
ranges and behavioral changes caused by human expansion, nondomestic felids are also a potential 
source [90-95]. Therefore, not only will intrasubtype recombination occur, but the development of new 
subtypes arising from recombination between strains from distinct clusters will become more likely [16, 
27, 31, 41, 47]. 
TM is encoded in the variable env gene and is mainly responsible for the host antibody response 
[61-63]. Mutations in the nucleotide sequence can lead to structural changes and result in antibodies 
unrecognizable by common diagnostic tests [53, 61-64]. In contrast, the capsid protein p24 and the 
matrix protein p15 are encoded in the gag region and are considered to be highly conserved [25, 61, 96]. 
Therefore, antibodies to these epitopes, if present, should be more consistently recognized, and it has 
been suggested that they be included in serological testing for FIV [53, 72]. Both gag proteins are used 
in the WB analysis as well as in one of the included POCT, the SNAPTM test, which is an ELISA-based 
test that also includes TM [53, 56, 70, 73, 74, 97]. The second POCT included in this study, the WITNESSR 
test, is an immune chromatography-based assay that detects antibodies directed against TM but not 
against gag proteins, similarly to the FIV-TM ELISA [56, 73, 98] used herein. Both POCT showed a low 
sensitivity in the present study when testing samples from cats with discordant results. Only five of the 
tested cats with discordant results (60 for the WITNESSR test and 52 for the SNAPTM test) had a positive 
POCT result; two of the POCT-positive results could be confirmed using RT-PCR. A third POCT double 
positive result was found in a kitten that was 3 months of age. In a follow-up sample collected at the 
age of 6 months, the kitten was shown to be FIV-negative by WB; thus, the initial POCT-positive results 
at 3 months were most likely due to maternal antibodies and the RT-PCR result was truly negative, 
since no viral RNA was present. The fourth SNAPTM POCT-positive cat was negative according to the 
WITNESSR POCT test as well as all RT-PCR methods employed. Because the age of this cat was not 
known and the SNAPTM signal was weak, the presence of maternal antibodies was not fully excludable. 
Two additional FIV WB-positive samples, which were found to be negative by FIV-TM ELISA and both 
POCT, were weakly positive according to either Fasttrack RT-PCR (CT-value of 37.8) or seminested RT-
PCR (very weak band). Thus, FIV infection could be confirmed using a different methodology to detect 
the virus itself instead of antibodies directed against the virus. The possibility cannot be completely 
excluded that these samples were collected during a very early infection before ample titers of 
antibodies had developed; the WB method might be somewhat more sensitive to this kind of early 
infection. However, we usually do not see both bands, p15 and p24, in the early phase of infection, 
which was the case in these two samples [52, 53, 72] . Overall, 247 samples in the present study showed 
inconclusive WB results with only the p24 or p15 band. Some of these samples might have originated 
from cats in an early FIV infection. In order to distinguish the latter from unspecific reactions, animals 
with inconclusive results according to WB are recommended to be retested two to three months later 
for a definite diagnosis. 
A limitation of this study is that the samples had been stored at -20°C for up to 20 years. However, 
antibodies are not sensitive to long-term storage at -20°C, and repeated freeze-thaw cycles have a 
minimal detrimental effect [99]. In contrast, viral RNA is very sensitive to degradation and might thus 
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have been lost during storage [100]. This might have contributed to the many negative RT-PCR results 
in the discordant samples, in addition to the expected low viral loads in many FIV-infected cats and 
sequence variation in the FIV genome, which might have led to a lack of recognition by the 
oligonucleotides used in the RT-PCR assays. All RT-PCR-positive samples showed very low viral loads 
that were too low for sequencing. Because of the long storage of many of the samples, repeated freeze-
thawing cycles, the limited sample volume and uncertainty concerning the sterility of the samples, we 
did not consider virus isolation from cell culture. Since not all discordant samples could be tested with 
all methods available in this study, it is difficult to compare the results of the different tests. However, 
overall, the SNAPTM POCT test seemed to have recognized more of the discordant samples than the 
WITNESSR POCT test. Two SNAPTM POCT-positive samples were negative according to the WITNESSR 
POCT. It is not quite clear why the SNAPTM POCT, which identifies the gp40, p15 and p24 antigens, did 
not detect all WB-positive samples, as antibodies against p15 and p24, two highly conserved antigens, 
were obviously present in the samples, since they had been recognized by WB. One argument for the 
enhanced sensitivity of WB compared to that of the SNAPTM test could be that the antigen concentration 
per strip and the accessibility of the antigen could be higher than that for the SNAPTM test, in which 
three antigens share one reaction field. We have no information on the exact antigens used in the 
different tests and the conformation and presentation of the antigens. Differences in the specificities of 
the antigens in the different tests, the import of new viruses and mutations, and the recombination of 
viruses and resulting changes in their antigens and the specificity of induced antibodies could have 
contributed to the discordant test results. Moreover, the sensitivity of the different tests could have 
played a role. This was obvious in one sample (sample ID 00005100) that was clearly positive in the 
SNAPTM POCT but negative in the WITNESSR POCT at the normal reading time point of 10 minutes and 
became weakly positive thereafter. Moreover, one sample (sample ID 00012612) was just at the cut-off 
point for a negative result (10%) for FIV-TM ELISA (9.9%). This sample was negative according to both 
the SNAPTM and WITNESSR POCT. As the results of all methods except FIV-TM ELISA are determined 
by visual inspection, positive samples could be falsely interpreted as negative if the colorimetric signal 
was not strong. It has been reported before that the sensitivities of the POCT used herein differ 
depending on the respective geographic location and the study cohort tested from 89%-100% for the 
SNAPTM test and 93.8%-100% for the WITNESSR test [68, 73, 98, 101-103]. 
The decreased sensitivity of FIV-TM ELISA described over the last twenty years was found based 
on a comparison with a study from 1995 [53]. The investigated samples in the current study were 
influenced by the number of samples submitted to our laboratory, the awareness of veterinarians of FIV 
infection in general and the necessity to test for FIV and to confirm POCT results as well as the 
geographic distribution of submitting customers. This has led to a high number of discordant samples, 
with up to 14 discordant samples per year in some years and little or no discordant samples in other 
years. Therefore, we were unable to determine whether the decrease in sensitivity occurred gradually 
over time and whether it poses an increasing problem, but overall it seems to be of significant relevance. 
In our study, the number of false-negative samples (n = 70) greatly surpassed the number of false-
positive samples (n = 11); the issue with false-positive results has been generally recognized in countries 
with a low FIV prevalence [56, 76, 78]. The majority of false-positive samples according to FIV-TM 
ELISA in our study were also false-positives when tested with the POCT, emphasizing the need for 
confirmation using WB to obtain a definitive FIV diagnosis. 
Finally, the discordant samples could also have been falsely WB-positive. We have chosen and 
used WB as the gold standard for detecting FIV infection for many years. In countries where no FIV 
vaccine is available, which is now the case for the US and has always been the case in Europe, WB is 
accepted as the gold standard for FIV diagnosis and for the confirmation of ambiguous and positive 
samples [56, 65, 70, 73-76, 104]. An alternative method for confirmation of presence or absence of FIV 
infection is virus isolation by cell culture. However, this method requires the purification and culture 
of fresh peripheral blood mononuclear cells from the cat under investigation ideally with cells from an 
uninfected cat; the method is laborious, expensive and time-consuming and is only offered in a few 
specialized laboratories [55, 56, 65, 67, 105]. No lymphocyte-containing fresh whole blood samples were 
available for this study, precluding this option. In agreement with good laboratory practice, we always
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 run negative and positive controls with each blot to control for false-positive or false-negative results 
[106]. Some of the discordant samples in this study could be confirmed to be positive either using one 
of the two POCT employed in this study or RT-PCR, even though some of the samples had been stored 
for a long time. Finally, there is evidence that WB is more robust for the detection of antibodies against 
a variety of felid lentiviruses: WB has been positively used in wild felid species, such as lions, cheetahs, 
leopards, or Geoffroy’s cats [3, 5, 6, 9, 53, 107-110]. For these reasons, we are quite confident that the 
WB-positive samples are from cats with true FIV infections. 
5. Conclusions 
In conclusion, FIV screening solely relying on antibodies directed against a single TM protein 
seems to be no longer adequate in geographic areas where cats with imported and new viruses must be 
expected. However, a POCT (SNAPTM FIV/FeLV Combo) using additional FIV antigens besides the 
immunodominant TM antigen did not recognize all the presumptively FIV-positive cats. Since ELISA 
and POCT are used for screening purposes, the inability to recognize an increasing number of FIV-
infected cats poses a serious problem. Currently, it is recommended to confirm any ELISA and POCT 
ambiguous or positive results in countries with a low FIV prevalence, since the positive predictive value 
of a positive ELISA and POCT result is low under these circumstances [56, 76, 78]. However, in light of 
our results, we now additionally recommend that any cat with a high suspicion of FIV infection and a 
negative FIV screening test be further investigated using WB for the purposes of confirmation to exclude 
false-negative results. Future prospective studies should aim to characterize in-depth fresh samples 
from cats with discordant results to identify the underlying viruses to further improve the laboratory 
diagnosis of FIV infection. 
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